24 May 2013 - Corgenix Medical (CONX.OB), a United States-based pharmaceutical company, has collaborated with Eli Lilly, a United States-based global pharmaceutical company.

It was reported yesterday that the collaboration is aimed at supporting Eli Lilly's oncology pipeline programme. It is a part of Corgenix' expanded contract services business unit for the healthcare and biotechnology industries.

The programme concentrates on advancing the proprietary diagnostic technology, originally developed by Lilly.

Financial terms of the deal have not been revealed.